DEC 0 6 2004 Substi

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				e required to respond to a collection of information unless it contains a valid OMB control number.  Complete if Known		
Substitu	de for form 1449/P	10		Application Number	10/711,101	
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	08/23/2004	
•	-		PPLICANT	First Named Inventor	George Blanck	
				Art Unit	1645	
	(Use as man	y sheets as n	ecessary)	Examiner Name	Unassigned	
Sheet	1	of	1	Attorney Docket Number	1372.183.PRC	

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No.1	Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of			
TV	1 ,	COENJAERTS, FRANK E.J. ET AL., The Oct-1 POU domain stimulates adenovirus DNA replication, The EMBO Journal, 1994, 5401-5409, 13(22),Oxford University Press.			
1	2	HINKLEY, CRAIG ET AL., Histone H2B Gene Transcription during Xenopus Early Development Requires Functional Cooperation, Molecular and Cellular Biology, 1992, 4400-4411, 12(10).			
	3	LAKIN, N.D. ET AL., Down Regulation of the octamer binding protein Oct- 1 during growth arrest, Molecular Brain Research, 1995, 47-54, Vol. 28.			
	4	MATHEOS, DIAMANTO D. ET AL., Oct-1 Enhances the In Vitro Replication of a Mammalian Autonomously Replicating DNA Sequence, J. of Cellular Biochemistry, 1998, 309-327, Vol. 68.			
	5 \	SHONA MURPHY, Differential in vivo activation of the class II and class III snRNA genes by the POU-specific domain of Oct-1, Nucleic Acids Research, 1997, 2068-2076, 25(11).			
	6 ,	QIN, XIAO-FENG ET AL., Transformation by homebox genes can be mediated by selective transcriptional represssion, The EMBO Journal, 1994, 5967-5976, 13(24), Oxford University.			
V	7	VAN LEEUWEN, HANS C. ET AL., The Oct-1 POU Homeodomain Stabilizes the Adenovirus Preinitiation Complex, J. of Biological Chemistry, 1997, 3398-3405, 272(6).			
	1 25				

	I = X	$^{\prime\prime}$		$\sim$				<del>,</del>	<del></del>	-
Examiner	1	7	\	П	101	Date	1 1	1011	lΛ/_	
Signature	/ /	١	Marcu 1	Ж	Invento,	Considered	II	271	00	_

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if hot in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

1 This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO To process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including to propading, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08A (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 14		d to respond to a collection of information unless it contains a valid OMB control number  Complete if Known			
Substitute for form 14	44/F10	Application Number	10/711,101		
(NIEODRA A	TION DISCLOSURE	Filing Date	08/23/2004		
	TION DISCLOSURE	First Named Inventor	George Blanck		
STATEME	NT BY APPLICANT	Art Unit	1645		
(Use as	many sheets as necessary)	Examiner Name	Unassigned		
Sheet 1	of 2	Attorney Docket Number	1372.183.PRC		

U. S. PATENT DOCUMENTS  Page Columns Lines With							
Examiner Initials*	Cite No.	Document Number  Number-Kind Code <sup>2 (f known)</sup>	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages. Columns, Lines, Where Relevant Passages or Relevan Figures Appear		
71/	1 .	<sup>US-</sup> 5,747,250	05-05-1998	Gruss et al.			
<del></del>		US-					
		US-					
		UŞ-					
<del></del>		US-					
		US-					
		US-					
		US-					
		US-					
····		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					
		US-					

		FORE	IGN PATENT DOCU	MENTS		
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	70
		Country Code <sup>3</sup> "Number <sup>4</sup> "Kind Code <sup>4</sup> (if known)	MM-DD-YYYY	<u> </u>	Or Relevant rigures Appear	<u> </u>
	ļ					-
					-	┢

Date Examiner menno Considered Signature

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the Individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Signature

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO **Application Number** 10/711,101 Filing Date INFORMATION DISCLOSURE 08/23/2004 STATEMENT BY APPLICANT First Named Inventor George Blanck Art Unit 1645 (Use as many sheets as necessary) **Examiner Name** Unassigned Attorney Docket Number 1372.183.PRC Sheel 2 2 of

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
TV	2 .	OSBORNE, AARON ET AL., Histone Deacetylase Activity Represses Gamma Interferon- Inducible HLA-DR Gene Expression,Molecular and Cell Biology, 2001, 6495-6506, 21(19).	
<del>,</del>			
	<del></del>		
Examiner Signature		Date Considered 12406	

\*EXAMINER: Initial if reference considered whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not

<sup>\*</sup>EXAMINER: Initial if reference considered whether or not distrious is nonformance with MPEP 809. Draw line through distrious in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique distrious designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.